Product Pipeline

From Bench to Bedside

Our lead product, CAP-1002, is an allogeneic cardiosphere-derived cell (CDC) product that we are currently developing for the treatment of heart disease associated with Duchenne muscular dystrophy (DMD) as well as adult cardiology conditions. Our exosome product, CAP-2003, is manufactured from CDCs and we expect to begin its clinical evaluation in 2017.

Capricor product-pipeline